#USA #Belgrade #Bone Graft #Xtant Medical #Trivium

Xtant Medical's Innovative Trivium™ Advanced Bone Graft

On April 23, 2025, Xtant Medical Holdings, Inc., a well-respected player in the global medical technology sector, proudly announced the launch of their latest innovation: Trivium™, an advanced demineralized bone matrix (DBM) allograft aimed at redefining the standard of care in bone grafting procedures. This new product comes armed with sophisticated technology and design, promising to boost performance in surgical applications.

What Makes Trivium™ Stand Out?

Trivium™ is not just another bone graft; it represents a significant leap forward, engineered with the PureLoc™ Fiber Technology that combines three synergistic elements. This unique design contributes to its remarkable structural integrity, ease of handling, and biological efficacy.

The architecture of Trivium™ features intertwined structures with interconnected porosity. This design is essential for promoting the attachment and growth of diverse cell types, establishing an optimum environment for robust tissue ingrowth. Through this innovative composition, the product aims to enhance healing processes and support regeneration effectively.

High Performance in Surgical Precision

One of the standout features of Trivium™ is its superior moldability and handling characteristics. Surgeons can easily manipulate the graft, which allows for precise application in a variety of surgical scenarios. Such versatility positions Trivium™ as an ideal choice for diverse orthopedic and spinal procedures well beyond traditional uses.

Trivium™ is processed through a proprietary method known as BacteRinse®, which has been clinically validated over two decades. This technique helps ensure the preservation of vital bone morphogenetic proteins (BMPs), creating a carefully crafted product that includes a full suite of bioavailable growth factors. Those growth factors are critical in initiating and supporting the bone repair process, thereby maximizing surgical outcomes.

Commitment to Innovation in Regenerative Medicine

Sean Browne, President and CEO of Xtant Medical, affirmed the company’s commitment by stating, "Trivium represents a significant advancement in bone grafting technology. By seamlessly integrating enhanced composition, high BMP retention, and versatile handling characteristics, we offer surgeons a reliable solution for various surgical applications. We are optimistic that Trivium will lead to consistent, dependable outcomes for patients."

Xtant Medical continues to innovate in the field of regenerative medicine, making strides to provide surgeons with high-performance grafts that support optimal patient outcomes. Trivium™ is now available through the company’s extensive nationwide distribution network, allowing it to reach healthcare professionals committed to delivering top-notch care.

A Vision Rooted in Integrity and Patient Care

The driving force behind Xtant Medical Holdings, Inc. is their mission to honor the gift of donation, aiming for their patients to live life to the fullest. The company dedicates itself to the research, development, and commercialization of crucial orthobiologics and spinal implant systems tailored for assisting complex spine procedures. The integrity of Xtant Medical’s staff ensures a focus on quality and customer service that is paramount in the medical industry.

As Xtant Medical rolls out Trivium™, it marks yet another chapter in their ongoing saga of innovation and commitment to advancing methodologies in surgical care. With this new offering, they reaffirm their position as trailblazers in the landscape of medical technology, set to enhance the lives of countless patients and their respective health journeys.